Crossref
News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017 Seattle, WA): A New Hope—Neoadjuvant BRAF/MEK Inhibition for BRAF-Mutated Stage III Melanoma
Clinical Skin Cancer · 2016
DOI: 10.1016/j.clsc.2017.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Skin Cancer, 2016. Verfasst von Alexander C.J. van Akkooi. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Akkooi, A. C. V. (2016). News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017 Seattle, WA): A New Hope—Neoadjuvant BRAF/MEK Inhibition for BRAF-Mutated Stage III Melanoma. Clinical Skin Cancer. https://doi.org/10.1016/j.clsc.2017.04.003
Vancouver
Akkooi ACV. News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017 Seattle, WA): A New Hope—Neoadjuvant BRAF/MEK Inhibition for BRAF-Mutated Stage III Melanoma. Clinical Skin Cancer. 2016. doi:10.1016/j.clsc.2017.04.003
BibTeX
@article{Akkooi2016,
author = {Akkooi, Alexander C.J. van},
title = {News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017 Seattle, WA): A New Hope—Neoadjuvant BRAF/MEK Inhibition for BRAF-Mutated Stage III Melanoma},
journal = {Clinical Skin Cancer},
year = {2016},
doi = {10.1016/j.clsc.2017.04.003}
}
EUVIMED